Screener
Cumberland Pharmaceuticals CPIX Q2 2026 earnings
Reported August 4, 2026 · After market close
Revenue$166.5KMiss by $8.3M
EPS-$0.20Miss by $0.07
Revenue estimate$8.5M
EPS estimate-$0.13
“The second quarter marked a defining milestone for Cumberland. With the successful completion of our Strategic Transaction, we have unlocked substantial value for our shareholders, while positioning Cumberland for its next phase as an innovation-focused biopharmaceutical company. We have strengthened our balance sheet, returned capital to shareholders through a special dividend and remain well-capitalized to advance our pipeline of differentiated product candidates designed to address significant unmet medical needs.”
Next report
Nov 3, 2026 (in 2 months)Revenue estimate$8.5M
EPS estimate-$0.13
Valuation & ratios
Segments
By product
Versus estimates
Revenue
Q2 2026$166.5KMiss by $8.3M
Q1 2026$9.1MBeat by $628.3KQ4 2025$13.7MBeat by $5.2MQ3 2025$8.3MQ2 2025$10.8MQ1 2025$11.7MDiluted EPS
Q2 2026-$0.20Miss by $0.07
Q1 2026-$0.13In lineQ4 2025-$0.01Beat by $0.12Q3 2025-$0.06Q2 2025$0.02Q1 2025$0.16FAQ
- When did Cumberland Pharmaceuticals report Q2 2026 earnings?
- Cumberland Pharmaceuticals (CPIX) reported Q2 2026 earnings on August 4, 2026 after market close.
- What were Cumberland Pharmaceuticals's Q2 2026 revenue and EPS?
- Cumberland Pharmaceuticals reported revenue of $166.5K and eps of $-0.20 for Q2 2026.
- Did Cumberland Pharmaceuticals beat estimates in Q2 2026?
- Revenue missed the consensus estimate of $8.5M by $8.3M. EPS missed the consensus estimate of $-0.13 by $0.07.
- How did Cumberland Pharmaceuticals's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 98.5% from $10.8M a year earlier.
- Where can I find Cumberland Pharmaceuticals's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001087294-26-000058) and the 10-Q periodic report (0001087294-26-000062) directly on SEC EDGAR. The filing index links above go to sec.gov.
